Patents Assigned to APEXIGEN, INC.
-
Patent number: 11078283Abstract: Provided are anti-programmed death-ligand 1 (PD-L1) monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of inflammatory and oncological diseases. Specifically, high affinity, humanized anti-PD-L1 antibodies are provided.Type: GrantFiled: January 17, 2019Date of Patent: August 3, 2021Assignee: Apexigen, Inc.Inventors: Pia Björck, Christine Tan, Erin Filbert, Xiaodong Yang
-
Patent number: 11001637Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.Type: GrantFiled: December 19, 2016Date of Patent: May 11, 2021Assignee: Apexigen, Inc.Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
-
Patent number: 10259878Abstract: The present invention provides anti-RANKL monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.Type: GrantFiled: March 11, 2014Date of Patent: April 16, 2019Assignee: APEXIGEN, INC.Inventors: Yongke Zhang, Xiaodong Yang, Guo-Liang Yu, Weimin Zhu
-
Patent number: 9994640Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.Type: GrantFiled: May 12, 2017Date of Patent: June 12, 2018Assignee: Apexigen, Inc.Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
-
Patent number: 9951136Abstract: The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.Type: GrantFiled: May 2, 2014Date of Patent: April 24, 2018Assignee: APEXIGEN, INC.Inventors: Sum Wai Pierre Lee, Yaohuang Ke, Yongke Zhang
-
Patent number: 9676861Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.Type: GrantFiled: October 30, 2013Date of Patent: June 13, 2017Assignee: Apexigen, Inc.Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
-
Patent number: 9556278Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.Type: GrantFiled: January 14, 2016Date of Patent: January 31, 2017Assignee: Apexigen, Inc.Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
-
Patent number: 9441042Abstract: The present invention provides anti-KDR monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant VEGF or KDR expression and/or activity.Type: GrantFiled: November 1, 2012Date of Patent: September 13, 2016Assignee: Apexigen, Inc.Inventors: Yaohuang Ke, Sum Wai Pierre Lee, Yongke Zhang, Guo-Liang Yu, Weimin Zhu
-
Patent number: 9266956Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.Type: GrantFiled: February 3, 2015Date of Patent: February 23, 2016Assignee: Apexigen, Inc.Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
-
Patent number: 9085621Abstract: The present invention provides anti-IL-1? monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of inflammatory and other diseases.Type: GrantFiled: September 9, 2011Date of Patent: July 21, 2015Assignee: Apexigen, Inc.Inventors: Yaohuang Ke, Sum Wai Pierre Lee, Yongke Zhang
-
Patent number: 8986692Abstract: The present invention provides an anti-VEGF monoclonal antibody, which has the variable region of heavy chain comprising the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and/or the variable region of light chain comprising the amino acid sequences of SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. The antibody can be produced by the cell line with the preservation number of CGMCC NO. 3233. The invention also provides the use of said antibody for the manufacture of medicaments for the treatment of a disease that is relevant to VEGF, wherein further provided are pharmaceutical composition, agents, kits and chips comprising said antibody, as well as the cell line with the preservation number of CGMCC NO. 3233.Type: GrantFiled: August 27, 2010Date of Patent: March 24, 2015Assignees: Jiangsu Simcere Pharmaceutical R & D Co., Ltd., Apexigen Inc.Inventors: Pierre Li, Yaohuang Ke, Yongke Zhang, Weimin Zhu, Guoliang Yu, Fanxin Ma, Xin Fan
-
Patent number: 8957193Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.Type: GrantFiled: June 5, 2014Date of Patent: February 17, 2015Assignee: Apexigen, Inc.Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
-
Publication number: 20140377282Abstract: The present invention provides anti-KDR monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant VEGF or KDR expression and/or activity.Type: ApplicationFiled: November 1, 2012Publication date: December 25, 2014Applicant: APEXIGEN, INC.Inventors: Yaohuang Ke, Sum Wai Pierre Lee, Yongke Zhang, Guo-Liang Yu, Weimin Zhu
-
Publication number: 20140349395Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.Type: ApplicationFiled: June 5, 2014Publication date: November 27, 2014Applicant: Apexigen, Inc.Inventors: Yongke ZHANG, Guo-Liang YU, Weimin ZHU
-
Publication number: 20140322239Abstract: The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.Type: ApplicationFiled: May 2, 2014Publication date: October 30, 2014Applicant: APEXIGEN, INC.Inventors: Sum Wai Pierre Lee, Yaohuang Ke, Yongke Zhang
-
Patent number: 8778345Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.Type: GrantFiled: April 27, 2012Date of Patent: July 15, 2014Assignee: Apexigen, Inc.Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
-
Patent number: 8753634Abstract: The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.Type: GrantFiled: February 28, 2012Date of Patent: June 17, 2014Assignee: Apexigen, Inc.Inventors: Sum Wai Pierre Lee, Yaohuang Ke, Yongke Zhang
-
Publication number: 20140120103Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.Type: ApplicationFiled: October 30, 2013Publication date: May 1, 2014Applicant: Apexigen, Inc.Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
-
Publication number: 20130330355Abstract: The present invention provides anti-IL-1? monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of inflammatory and other diseases.Type: ApplicationFiled: September 9, 2011Publication date: December 12, 2013Applicant: APEXIGEN, INC.Inventors: Yaohuang Ke, Sum Wai Pierre Lee, Yongke Zhang
-
Publication number: 20120231011Abstract: The present invention provides an anti-VEGF monoclonal antibody, which has the variable region of heavy chain comprising the amino acid sequences of SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3, and/or the variable region of light chain comprising the amino acid sequences of SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6. The antibody can be produced by the cell line with the preservation number of CGMCC NO. 3233. The invention also provides the use of said antibody for the manufacture of medicaments for the treatment of a disease that is relevant to VEGF, wherein further provided are pharmaceutical composition, agents, kits and chips comprising said antibody, as well as the cell line with the preservation number of CGMCC NO. 3233.Type: ApplicationFiled: August 27, 2010Publication date: September 13, 2012Applicants: Apexigen Inc., Jiangsu Simcere Pharmaceutical R&D Co., LtdInventors: Pierre Li, Yaohuang ke, Yongke Zhang, Weimin Zhu, Guoliang Yu, Fanxin Ma, Xin Fan